



IAS PARLIAMENT

Information is Empowering
A Shankar IAS Academy Initiative

Ailing Indian pharma industry

What is the issue?

\n\n

India's champion generic drug industry which has a global presence is losing its sheen.

\n\n

What are the causes?

\n\n

- \n
- Indian pharmaceuticals are heavily dependent on the US market.
\n
- Tightening regulations and inspections by international drug control regulators like the US Food and Drug Administration (FDA) is a hindrance.
\n
- FDA has streamlined its processes and is now fast-tracking approvals for new generic drugs which is a good thing.
\n
- However it means that competition in the marketplace has stepped up dramatically as well as prices are getting competitive.
\n
- Indian drug companies are also uncertain due to speculations with Trump's emphasis of manufacturing in America.
\n

\n\n

What are the desired actions?

\n\n

- \n
- Indian companies should start making more niche creations that will give

them better pricing leverage.

\n

- Need for stepping up R&D spending.

\n

\n\n

\n\n

Source: The Hindu - BussinessLine

\n



IAS PARLIAMENT

Information is Empowering

A Shankar IAS Academy Initiative